Amgen is paying Kyowa Kirin $400 million to share in the development of a drug that could offer a new approach to treating atopic dermatitis, a form of eczema. The deal comes months after Japan-based Kyowa Kirin reported positive preliminary Phase 2 data for its antibody.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Doximity, the “LinkedIn for physicians,” is preparing for an IPO. In an unusual move, it’s setting aside a portion of its shares for some of its users.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
What does a former Seema Verma advisor think of Brooks-LaSure, the incoming CMS administrator?
What does a former Seema Verma advisor think of Brooks-LaSure, the incoming CMS administrator?
To know how Chiquita Brooks-LaSure will lead the Centers for Medicare and Medicaid Services, we sat down with Matthew Hittle, a former senior adviser to Seema Verma, who led the agency under the former president.
Shares0
HHS Secretary Xavier Becerra and Chiquita Brooks-LaSure at her swearing in ceremony on May 27.
Last week, U.S. Senators narrowly confirmed Chiquita Brooks-LaSure as administrator of the Centers for Medicare & Medicaid Services (CMS), entrusting this veteran health policy advisor with the critical role that has been vacant since Seema Verma stepped down in January.